Using Literature-Based Discovery to Explain Adverse Drug Effects
We report on our research in using literature-based discovery (LBD) to provide pharmacological and/or pharmacogenomic explanations for reported adverse drug effects. The goal of LBD is to generate novel and potentially useful hypotheses by analyzing the scientific literature and optionally some additional resources. Our assumption is that drugs have effects on some genes or proteins and that these genes or proteins are associated with the observed adverse effects. Therefore, by using LBD we try to find genes or proteins that link the drugs with the reported adverse effects. These genes or proteins can be used to provide insight into the processes causing the adverse effects. Initial results show that our method has the potential to assist in explaining reported adverse drug effects.
KeywordsLiterature-based discovery Text mining Pharmacovigilance Adverse drug effects Adverse drug reactions Pharmacogenomics
This work was supported in part by the Intramural Research Program of the U.S. National Institutes of Health, National Library of Medicine. Authors would like to thank Celine Narjoz and Marie-Anne Loriot for suggesting the additional adverse drug reactions, which we used in this study. We are also grateful for the contribution of the medical students (Faculty of Medicine, University of Maribor) in the evaluation of the extracted relations.
- 11.Hristovski D., SemBT. http://sembt.mf.uni-lj.si. 2009.
- 19.Kuhn, J. G., Pharmacology of irinotecan. Oncology (Williston Park) 12:39–42, 1998.Google Scholar
- 26.Yang, S.-H., Choi, J.-S., and Choi, D.-H., Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88:1–9, 2011. doi: 10.1159/000328773.CrossRefPubMedGoogle Scholar
- 27.Dopazo, C., Bilbao, I., Lázaro, J. L., et al., Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant. Proc. 41:1021–4, 2009. doi: 10.1016/j.transproceed.2009.02.019.CrossRefPubMedGoogle Scholar